EP 202: Biotech at the intersection of science and politics with Max Bronstein of Aviva Strategies

<p>This week on The Genetics Podcast, Patrick is joined by Max Bronstein, CEO of Aviva Strategies. They discuss the shifting regulatory and political landscape shaping biotech, the realities of today’s drug development process, and why new incentives and flexible trial pathways are critical to advancing rare and ultra-rare disease therapies.</p><p><strong>Show Notes: </strong></p><p><strong>0:00 </strong>Intro to The Genetics Podcast</p><p><strong>00:59</strong> Welcome to Max</p><p><strong>01:51</strong> Regulatory shifts and FDA challenges under the new administration</p><p><strong>05:40 </strong>Overview of the regulatory process for therapeutic development and the push for patient-centered trials</p><p><strong>11:26</strong> Challenges in drug development from regulatory gaps to shifting FDA priorities</p><p><strong>15:45 </strong>Unprecedented government turnover and its impact on biotech industry stability</p><p><strong>18:32 </strong>Status and significance of the pediatric prio...